What's hot

View all perspectives
      Prediction of PsA in PSO pts: does it work?

      First predictive model using mainly clinical data and labs extracted from p

      Aurelie Najm AurelieRheumo

      3 months ago
      Prediction of PsA in PSO pts: does it work? First predictive model using mainly clinical data and labs extracted from primary care Performs well in the cohort it was trained w/ but not in validation cohort. Often an issue with prediction models! Needs more granularity than https://t.co/5cVgqfd4fX
      ‼️Diagnosis of axSpA is clinical
      -MRI is a tool but still has a lot of limitations.
      -Improve reports by directly com

      Adela Castro AdelaCastro222

      3 months ago
      ‼️Diagnosis of axSpA is clinical -MRI is a tool but still has a lot of limitations. -Improve reports by directly communicating with radiology and be specific on pt clinical info. -Unified algorithms are needed to apply AI in dx of SIJ inflammation on MRI. #EULAR2025 @RheumNow https://t.co/9GR6FsgIcL
      Is #PDE5i protective in development of
      #SSc #ILD?

      Maybe

      444 w ILD of >4000 #EUSTAR Pts over 1 to 2 yrs f/u

      #imm

      Janet Pope Janetbirdope

      3 months ago
      Is #PDE5i protective in development of #SSc #ILD? Maybe 444 w ILD of >4000 #EUSTAR Pts over 1 to 2 yrs f/u #immunesuppressive use maybe or not 🤷‍♀️channeling bias Reduction in new #ILD in #scleroderma PDE5i ✅ Immunesuppression ? @RheumNow #EULAR2025 @eular_org #OP0334 https://t.co/6dtLfybkRV
      #EULAR2025 Take Home message from Updated EULAR Recommendations @eular_org for #Lupus Nephritis:

      -Kidney Biopsy vital
      -

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months ago
      #EULAR2025 Take Home message from Updated EULAR Recommendations @eular_org for #Lupus Nephritis: -Kidney Biopsy vital -Early use of Combination Therapies (HCQ + GC + Immunosuppressant + CNI/Belimumab/Obinutuzumab) -Severe: High dose Cyclo + GC @RheumNow https://t.co/jHFqdT1TLf
      🔍MRI lesions in early axSpA vs non axSpA with chronic back pain:
      -Data from SPACE cohort
      -n 318 (214 axSpA vs 108 non

      Adela Castro AdelaCastro222

      3 months ago
      🔍MRI lesions in early axSpA vs non axSpA with chronic back pain: -Data from SPACE cohort -n 318 (214 axSpA vs 108 non-axSpA). -Baseline imaging (CR and MRI) and at 2y f/u -Minimal progression on CR in both early axSpA and non-axSpA CBP. -On MRI, significant increase in the https://t.co/m5YOAiFUz1
      E3N cohort 78000+ women >30yrs follow up
      698 incident RA cases)

      In non smokers, RA asso w/
      -tall at birth HR=1.55

      I

      Aurelie Najm AurelieRheumo

      3 months ago
      E3N cohort 78000+ women >30yrs follow up 698 incident RA cases) In non smokers, RA asso w/ -tall at birth HR=1.55 In smokers, RA risk associated w/ -prematurity HR=1.63 -in utero exposure to tobacco HR=1.83 (ns) #EULAR2025 @RheumNow POS0226 https://t.co/xC3k3kiKsZ
      PsA asso w/ higher risk of preterm births in women

      Scandinavian registries
      688 PsA pregnancies

      8% preterm births vs.

      Aurelie Najm AurelieRheumo

      3 months ago
      PsA asso w/ higher risk of preterm births in women Scandinavian registries 688 PsA pregnancies 8% preterm births vs. 4.5% general population OR 1.8 16.4% if bDMARD combination OR 4 3.1% if bDMARD monotherapy OR 0.7 bDMARDs combo probably a surrogate of high disease activity
      Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors

      The concept of D2M axSpA is a recent development, w

      Dr. John Cush RheumNow

      3 months ago
      Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors The concept of D2M axSpA is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. https://t.co/KmfJvAtwp0
      RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. A

      Dr. John Cush RheumNow

      3 months ago
      RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty.
      Live Daily Eular 2025 Recap Day 2 https://t.co/78NYTcFPG6

      Dr. John Cush RheumNow

      3 months ago
      Live Daily Eular 2025 Recap Day 2 https://t.co/78NYTcFPG6
      Secukinumab promise in PMR is real

      GCA is getting steroid-sparing therapy choices, and PMR doesn’t want to miss out.

      Dr. John Cush RheumNow

      3 months ago
      Secukinumab promise in PMR is real GCA is getting steroid-sparing therapy choices, and PMR doesn’t want to miss out. Most PMR patients with current therapy approaches incur multiple grams of cumulative prednisolone exposure, even though they’re often exactly the kind of https://t.co/GuD0l7zSfj
      Among 200 #axSpA pts from Rheumazentrum Ruhrgebiet

      🔴Performance tests (SPPB)
      were associated with
      🔴Global fun

      Nelly ZIADE 🍀 Nellziade

      3 months ago
      Among 200 #axSpA pts from Rheumazentrum Ruhrgebiet 🔴Performance tests (SPPB) were associated with 🔴Global functioning and health (ASAS-HI and other PROs) What does this mean? Improving physical performance could enhance PROs & QOL #EULAR2025 POS# @RheumNow @XBaraliakos https://t.co/P3Q5NDvtoj
      #D2M_axSpA_saga 🇬🇷

      Prevalence of D2M axSpA in 395 patients: 10.1%

      Associated factors:
      🔹️High disease activ

      Nelly ZIADE 🍀 Nellziade

      3 months ago
      #D2M_axSpA_saga 🇬🇷 Prevalence of D2M axSpA in 395 patients: 10.1% Associated factors: 🔹️High disease activity at diagnosis 🔹️Comorbidities (high BMI, smoking, depression) 🔹️Unemployment Kougkas et al. POS#0121 #EULAR2025 @rheumnow https://t.co/vcPcTATTx5
      What's the difference between PIPsA & NIPsA?

      (Persistent Inflammatory confirmed by IMAGING
      vs. Non inflammatory Ps

      Nelly ZIADE 🍀 Nellziade

      3 months ago
      What's the difference between PIPsA & NIPsA? (Persistent Inflammatory confirmed by IMAGING vs. Non inflammatory PsA) 🔹️Cross-sectional study 🔹️517 pts under b/tsDMARDs 🔹️10.3% D2T 🔹️57% PIPsA / 43% NIPsA 👇 Distinct phenotypes 👇 OP0176 #EULAR2025 @rheumnow https://t.co/YGHpbeE6ws
      What happens to the prevalence of D2T PsA if we use different parameters in its definition?

      Data from 5 Nordic registri

      Nelly ZIADE 🍀 Nellziade

      3 months ago
      What happens to the prevalence of D2T PsA if we use different parameters in its definition? Data from 5 Nordic registries including 13,872 patients showed a variation from 37% (less stringent) to 0.6% (more stringent)! OP0177 #EULAR2025 @rheumnow https://t.co/QbF15t3Zrz
      How well do you know this week's rheumatology news?
      Take the rheumIQ quiz
      Take the RheumIQ Quiz

      Podcasts

      • EULAR 2025 Rheumatology RoundUp Hosted by Dr. John J. Cush and Dr. Arthur Kavanaugh
      • EULAR 2025 - Day 9 podcast
      • EULAR 2025 - Day 8 podcast

      Catch up on Conference Podcasts

      ×